The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

GSK Plc ’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in 2024 ...

Investing.com -- GSK Plc's CEO Emma Walmsley has expressed intentions to engage in more business deals, as the British pharmaceutical company intensifies its focus on cancer treatments. This comes ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx will ...